Oncology Today with Dr Neil Love cover image

Management of HER2-Altered Non-Small Cell Lung Cancer

Oncology Today with Dr Neil Love

00:00

TDXD and HER2M-Mutin Lung Cancer - What Are the Side Effects?

The mechanism of action is quite different compared to the EGFR TKIs, so there are some corollaries, some areas of similarity. Overall, I don't think they can be judged the same way. And it is kind of like a smart targeted chemotherapy, so I'd see it like a precision chemotherapy, so to speak. The response rates have been about 50 to 60%. And interestingly, I'm seeing some immune effects. Some of my patients, you know, even treated off protocol, they've, some of them respond very quickly in the first scan, get a partial response. But some of my patients actually get stable disease for a year and a half, and then they

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app